X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DIVIS LABORATORIES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DIVIS LABORATORIES PFIZER/
DIVIS LABORATORIES
 
P/E (TTM) x 24.2 17.8 135.7% View Chart
P/BV x 3.8 3.9 99.7% View Chart
Dividend Yield % 0.8 1.6 52.5%  

Financials

 PFIZER   DIVIS LABORATORIES
EQUITY SHARE DATA
    PFIZER
Mar-16
DIVIS LABORATORIES
Mar-16
PFIZER/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,7242,484 109.7%   
Low Rs1,611918 175.5%   
Sales per share (Unadj.) Rs440.9142.3 309.9%  
Earnings per share (Unadj.) Rs48.741.9 116.3%  
Cash flow per share (Unadj.) Rs75.846.3 163.5%  
Dividends per share (Unadj.) Rs15.0010.00 150.0%  
Dividend yield (eoy) %0.70.6 117.7%  
Book value per share (Unadj.) Rs462.9161.5 286.6%  
Shares outstanding (eoy) m45.75265.47 17.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.912.0 41.1%   
Avg P/E ratio x44.540.6 109.6%  
P/CF ratio (eoy) x28.636.7 77.9%  
Price / Book Value ratio x4.710.5 44.5%  
Dividend payout %30.823.9 129.0%   
Avg Mkt Cap Rs m99,163451,525 22.0%   
No. of employees `0002.93.7 77.9%   
Total wages/salary Rs m2,7583,649 75.6%   
Avg. sales/employee Rs Th6,981.710,184.4 68.6%   
Avg. wages/employee Rs Th954.5984.1 97.0%   
Avg. net profit/employee Rs Th771.12,998.5 25.7%   
INCOME DATA
Net Sales Rs m20,17037,764 53.4%  
Other income Rs m857848 101.1%   
Total revenues Rs m21,02838,612 54.5%   
Gross profit Rs m4,31014,138 30.5%  
Depreciation Rs m1,2391,182 104.8%   
Interest Rs m523 22.4%   
Profit before tax Rs m3,92313,781 28.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7942,662 67.4%   
Profit after tax Rs m2,22811,119 20.0%  
Gross profit margin %21.437.4 57.1%  
Effective tax rate %45.719.3 236.7%   
Net profit margin %11.029.4 37.5%  
BALANCE SHEET DATA
Current assets Rs m16,29930,947 52.7%   
Current liabilities Rs m7,5945,195 146.2%   
Net working cap to sales %43.268.2 63.3%  
Current ratio x2.16.0 36.0%  
Inventory Days Days65117 55.9%  
Debtors Days Days2685 30.2%  
Net fixed assets Rs m8,62217,027 50.6%   
Share capital Rs m458531 86.2%   
"Free" reserves Rs m20,72242,341 48.9%   
Net worth Rs m21,18042,877 49.4%   
Long term debt Rs m255 531.9%   
Total assets Rs m29,13749,684 58.6%  
Interest coverage x755.5595.0 127.0%   
Debt to equity ratio x00 1,076.8%  
Sales to assets ratio x0.70.8 91.1%   
Return on assets %7.722.4 34.2%  
Return on equity %10.525.9 40.6%  
Return on capital %19.032.2 59.0%  
Exports to sales %0.185.3 0.1%   
Imports to sales %17.522.9 76.3%   
Exports (fob) Rs m1232,198 0.0%   
Imports (cif) Rs m3,5268,654 40.7%   
Fx inflow Rs m5232,270 0.2%   
Fx outflow Rs m1408,775 1.6%   
Net fx Rs m-8823,496 -0.4%   
CASH FLOW
From Operations Rs m3,43610,379 33.1%  
From Investments Rs m-6,991-4,135 169.1%  
From Financial Activity Rs m-619-6,241 9.9%  
Net Cashflow Rs m-4,1743 -126,469.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 4.9 19.0 25.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.2 137.8%  
Shareholders   85,207 31,796 268.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 21, 2017 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS